Eculizumab is a humanized monoclonal antibody that targets C5. Therapy with eculizumab prevents activation of the subsequent elements of the terminal complement cascade (C6, C7, C8, C9). This blockage places the patient at risk for infections with Neisseria species, similar to the risk seen in a patient with a hereditary deficiency affecting one of these components of the terminal complement cascade.